Journal articles: 'Cancer Cell Imaging'

1

Ray, L. Bryan. "Imaging cancer cell by cell." Science 372, no. 6543 (May 13, 2021): 699.1–699. http://dx.doi.org/10.1126/science.372.6543.699-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Roy, Catherine, Xavier Buy, and Sofiane el Ghali. "Imaging in Renal Cell Cancer." EAU Update Series 1, no. 4 (December 2003): 209–14. http://dx.doi.org/10.1016/s1570-9124(03)00058-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ponomarev, V. "Nuclear Imaging of Cancer Cell Therapies." Journal of Nuclear Medicine 50, no. 7 (June 12, 2009): 1013–16. http://dx.doi.org/10.2967/jnumed.109.064055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Heidenreich, Axel, and Vincent Ravery. "Preoperative imaging in renal cell cancer." World Journal of Urology 22, no. 5 (July 30, 2004): 307–15. http://dx.doi.org/10.1007/s00345-004-0411-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Irshad, Abid, and James G. Ravenel. "Imaging of small-cell lung cancer." Current Problems in Diagnostic Radiology 33, no. 5 (September 2004): 200–211. http://dx.doi.org/10.1067/j.cpradiol.2004.06.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

PINNER, S., and E. SAHAI. "Imaging amoeboid cancer cell motilityin vivo." Journal of Microscopy 231, no. 3 (September 2008): 441–45. http://dx.doi.org/10.1111/j.1365-2818.2008.02056.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Midde, Krishna, Nina Sun, Cristina Rohena, Linda Joosen, Harsharan Dhillon, and Pradipta Ghosh. "Single-Cell Imaging of Metastatic Potential of Cancer Cells." iScience 10 (December 2018): 53–65. http://dx.doi.org/10.1016/j.isci.2018.11.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yano, Shuya, and Robert Hoffman. "Real-Time Determination of the Cell-Cycle Position of Individual Cells within Live Tumors Using FUCCI Cell-Cycle Imaging." Cells 7, no. 10 (October 14, 2018): 168. http://dx.doi.org/10.3390/cells7100168.

Full text

Abstract:

Most cytotoxic agents have limited efficacy for solid cancers. Cell-cycle phase analysis at the single-cell level in solid tumors has shown that the majority of cancer cells in tumors is not cycling and is therefore resistant to cytotoxic chemotherapy. Intravital cell-cycle imaging within tumors demonstrated the cell-cycle position and distribution of cancer cells within a tumor, and cell-cycle dynamics during chemotherapy. Understanding cell-cycle dynamics within tumors should provide important insights into novel treatment strategies.

APA, Harvard, Vancouver, ISO, and other styles

9

A. Rabinovich, Brian, and Caius G. Radu. "Imaging Adoptive Cell Transfer Based Cancer Immunotherapy." Current Pharmaceutical Biotechnology 11, no. 6 (September 1, 2010): 672–84. http://dx.doi.org/10.2174/138920110792246528.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liu, Gang, Magdalena Swierczewska, Gang Niu, Xiaoming Zhang, and Xiaoyuan Chen. "Molecular imaging of cell-based cancer immunotherapy." Molecular BioSystems 7, no. 4 (2011): 993. http://dx.doi.org/10.1039/c0mb00198h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lucignani, Giovanni, Luisa Ottobrini, Cristina Martelli, Maria Rescigno, and Mario Clerici. "Molecular imaging of cell-mediated cancer immunotherapy." Trends in Biotechnology 24, no. 9 (September 2006): 410–18. http://dx.doi.org/10.1016/j.tibtech.2006.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Munden, Reginald F., and John Bruzzi. "Imaging of Non–Small Cell Lung Cancer." Radiologic Clinics of North America 43, no. 3 (May 2005): 467–80. http://dx.doi.org/10.1016/j.rcl.2005.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ibraheem, Sumayah, Afraa Ali Kadhim, Kadhim Ali Kadhim, Ihssan A. Kadhim, and Majid Jabir. "Zinc Oxide Nanoparticles as Diagnostic Tool for Cancer Cells." International Journal of Biomaterials 2022 (November 2, 2022): 1–10. http://dx.doi.org/10.1155/2022/2807644.

Full text

Abstract:

ZnO nanoparticles have various characteristics that make them attractive to be used in many medical applications like a cancer diagnosis. It can be used as a nanoprobe for targeting different types of cancer cells in vitro as a cancer cell recognition system. The present study aims to investigate the permeability of ZnO NPs through both normal and cancerous cell lines in humans. In vitro experiments for ZnO NPs inside the environment of living cells have been described, which would contribute to the visualization of nanoparticles as cancer diagnostic and scanning techniques. MCF7, AMJ13, and RD cancer cells, and also the normal breast cell line HBL, were used in in vitro imaging experiments. The findings revealed that ZnO NPs specifically incorporated within tumor cells while accumulating less inside normal cells. Our findings show that ZnO NPs may be identified inside cancer cells after 1 h of exposure and can endure up to 3 h, providing them appropriate for tumor cell imaging. The findings showed that ZnO NPs might be employed as an alternate fluorophore for diagnostic imaging in the early identification of solid cancers. Therefore, here we studied in vitro applications of ZnO NPs and their beneficial use as a diagnostic tool for cancer cell lines rather than normal cells. Taken together, ZnO NPs can be used as good targeting NPs for the development of imaging agents for early diagnosis of cancers.

APA, Harvard, Vancouver, ISO, and other styles

14

Zager, Jonathan S., Simon Brodsky, and Claudia G. Berman. "Imaging of Merkel Cell Carcinoma." Current Problems in Cancer 34, no. 1 (January 2010): 65–76. http://dx.doi.org/10.1016/j.currproblcancer.2010.01.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Ermis, Menekse, Ezgi Antmen, Ozgur Kuren, Utkan Demirci, and Vasif Hasirci. "A Cell Culture Chip with Transparent, Micropillar-Decorated Bottom for Live Cell Imaging and Screening of Breast Cancer Cells." Micromachines 13, no. 1 (January 7, 2022): 93. http://dx.doi.org/10.3390/mi13010093.

Full text

Abstract:

In the recent years, microfabrication technologies have been widely used in cell biology, tissue engineering, and regenerative medicine studies. Today, the implementation of microfabricated devices in cancer research is frequent and advantageous because it enables the study of cancer cells in controlled microenvironments provided by the microchips. Breast cancer is one of the most common cancers in women, and the way breast cancer cells interact with their physical microenvironment is still under investigation. In this study, we developed a transparent cell culture chip (Ch-Pattern) with a micropillar-decorated bottom that makes live imaging and monitoring of the metabolic, proliferative, apoptotic, and morphological behavior of breast cancer cells possible. The reason for the use of micropatterned surfaces is because cancer cells deform and lose their shape and acto-myosin integrity on micropatterned substrates, and this allows the quantification of the changes in morphology and through that identification of the cancerous cells. In the last decade, cancer cells were studied on micropatterned substrates of varying sizes and with a variety of biomaterials. These studies were conducted using conventional cell culture plates carrying patterned films. In the present study, cell culture protocols were conducted in the clear-bottom micropatterned chip. This approach adds significantly to the current knowledge and applications by enabling low-volume and high-throughput processing of the cell behavior, especially the cell–micropattern interactions. In this study, two different breast cancer cell lines, MDA-MB-231 and MCF-7, were used. MDA-MB-231 cells are invasive and metastatic, while MCF-7 cells are not metastatic. The nuclei of these two cell types deformed to distinctly different levels on the micropatterns, had different metabolic and proliferation rates, and their cell cycles were affected. The Ch-Pattern chips developed in this study proved to have significant advantages when used in the biological analysis of live cells and highly beneficial in the study of screening breast cancer cell–substrate interactions in vitro.

APA, Harvard, Vancouver, ISO, and other styles

16

Manabe, Tomoko, Yoshinobu Hirose, Takuji Kiryuu, Hiroshi Koudo, and Hiroaki Hoshi. "Magnetic Resonance Imaging of Endometrial Cancer and Clear Cell Cancer." Journal of Computer Assisted Tomography 31, no. 2 (March 2007): 229–35. http://dx.doi.org/10.1097/01.rct.0000238005.42129.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Whyard, Terry, Wayne C. Waltzer, Douglas Waltzer, and Victor Romanov. "Metabolic alterations in bladder cancer: applications for cancer imaging." Experimental Cell Research 341, no. 1 (February 2016): 77–83. http://dx.doi.org/10.1016/j.yexcr.2016.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hart, Lori S., and Wafik S. El-Deiry. "Invincible, but Not Invisible: Imaging Approaches Toward In Vivo Detection of Cancer Stem Cells." Journal of Clinical Oncology 26, no. 17 (June 10, 2008): 2901–10. http://dx.doi.org/10.1200/jco.2008.16.9573.

Full text

Abstract:

With evidence emerging in support of a cancer stem-cell model of carcinogenesis, it is of paramount importance to identify and image these elusive cells in their natural environment. The cancer stem-cell hypothesis has the potential to explain unresolved questions of tumorigenesis, tumor heterogeneity, chemotherapeutic and radiation resistance, and even the metastatic phenotype. Intravital imaging of cancer stem cells could be of great value for determining prognosis, as well as monitoring therapeutic efficacy and influencing therapeutic protocols. Cancer stem cells represent a rare population of cells, as low as 0.1% of cells within a human tumor, and the phenotype of isolated cancer stem cells is easily altered when placed under in vitro conditions. This represents a challenge in studying cancer stem cells without manipulation or extraction from their natural environment. Advanced imaging techniques allow for the in vivo observation of physiological events at cellular resolution. Cancer stem-cell studies must take advantage of such technology to promote a better understanding of the cancer stem-cell model in relation to tumor growth and metastasis, as well as to potentially improve on the principles by which cancers are treated. This review examines the opportunities for in vivo imaging of putative cancer stem cells with regard to currently accepted cancer stem-cell characteristics and advanced imaging technologies.

APA, Harvard, Vancouver, ISO, and other styles

19

Yano, Shuya, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara, and Robert M. Hoffman. "FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells." Cancers 12, no. 9 (September 17, 2020): 2655. http://dx.doi.org/10.3390/cancers12092655.

Full text

Abstract:

Progress in chemotherapy of solid cancer has been tragically slow due, in large part, to the chemoresistance of quiescent cancer cells in tumors. The fluorescence ubiquitination cell-cycle indicator (FUCCI) was developed in 2008 by Miyawaki et al., which color-codes the phases of the cell cycle in real-time. FUCCI utilizes genes linked to different color fluorescent reporters that are only expressed in specific phases of the cell cycle and can, thereby, image the phases of the cell cycle in real-time. Intravital real-time FUCCI imaging within tumors has demonstrated that an established tumor comprises a majority of quiescent cancer cells and a minor population of cycling cancer cells located at the tumor surface or in proximity to tumor blood vessels. In contrast to most cycling cancer cells, quiescent cancer cells are resistant to cytotoxic chemotherapy, most of which target cells in S/G2/M phases. The quiescent cancer cells can re-enter the cell cycle after surviving treatment, which suggests the reason why most cytotoxic chemotherapy is often ineffective for solid cancers. Thus, quiescent cancer cells are a major impediment to effective cancer therapy. FUCCI imaging can be used to effectively target quiescent cancer cells within tumors. For example, we review how FUCCI imaging can help to identify cell-cycle-specific therapeutics that comprise decoy of quiescent cancer cells from G1 phase to cycling phases, trapping the cancer cells in S/G2 phase where cancer cells are mostly sensitive to cytotoxic chemotherapy and eradicating the cancer cells with cytotoxic chemotherapy most active against S/G2 phase cells. FUCCI can readily image cell-cycle dynamics at the single cell level in real-time in vitro and in vivo. Therefore, visualizing cell cycle dynamics within tumors with FUCCI can provide a guide for many strategies to improve cell-cycle targeting therapy for solid cancers.

APA, Harvard, Vancouver, ISO, and other styles

20

Tan, Mingqian, Nirun Jatupaiboon, Yizhe Song, Guangwei Sun, and Xiaojun Ma. "Hollow silica nanoparticles as imaging agent carriers for cancer cell imaging." Journal of Controlled Release 172, no. 1 (November 2013): e57. http://dx.doi.org/10.1016/j.jconrel.2013.08.118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Mei, Xin, Yin-Sheng Chen, Fu-Rong Chen, Shao-Yan Xi, and Zhong-Ping Chen. "Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging." Neuro-Oncology 19, no. 8 (March 8, 2017): 1109–18. http://dx.doi.org/10.1093/neuonc/nox016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Chen, Yun, Jing Ye, Gang Lv, Weiwei Liu, Hui Jiang, Xiaohui Liu, and Xuemei Wang. "Hydrogen Peroxide and Hypochlorite Responsive Fluorescent Nanoprobes for Sensitive Cancer Cell Imaging." Biosensors 12, no. 2 (February 11, 2022): 111. http://dx.doi.org/10.3390/bios12020111.

Full text

Abstract:

Accurate diagnosis of cancer cells directly affects the clinical treatment of cancer and can significantly improve the therapeutic effect of cancer patients. Cancer cells have a unique microenvironment with a large amount of peroxide inside, effectively differentiated from relevant microenvironment normal cells. Therefore, designing the high-sensitive probes to recognize and distinguish the special physiological microenvironment of cancer cells can shed light on the early diagnosis of cancers. In this article, we design and construct a fluorescence (FL) contrast agent for cancer cell recognition and imaging analysis. Firstly, luminol-gold NPs (Lum-AuNPs) have been initially built, and then successfully loaded with the fluorescent receptor Chlorin e6 (Ce6) to prepare the luminescent nanoprobes (Ce6@Lum-AuNPs) with green synthesis, i.e., with biocompatible agents and mild temperature. The as-prepared fluorescent Ce6@Lum-AuNPs can efficiently and sensitively realize FL bioimaging of cancer cells. The relevant bio-sensing mechanism pertains to the presence of hypochlorite (ClO−); hydrogen peroxide (H2O2) in cancer cells could readily interact with luminol to produce chemiluminescence, which can activate the Ce6 component to emit near-infrared (NIR) FL. Therefore, this raises the possibility of utilizing the Ce6@Lum-AuNPs as efficient fluorescent nanoprobes for promising cancer early diagnosis and other relevant disease bioanalysis.

APA, Harvard, Vancouver, ISO, and other styles

23

Wang, Chao, Baoli Dong, Xiuqi Kong, Xuezhen Song, Nan Zhang, and Weiying Lin. "A cancer cell-specific fluorescent probe for imaging Cu 2+ in living cancer cells." Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 182 (July 2017): 32–36. http://dx.doi.org/10.1016/j.saa.2017.03.058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ding, Wen-Qiang, Si-Yong Qin, Yin-Jia Cheng, Yi-Han Ma, and Ai-Qing Zhang. "Novel oligopeptide nanoprobe for targeted cancer cell imaging." RSC Advances 8, no. 54 (2018): 30887–93. http://dx.doi.org/10.1039/c8ra06034g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Reya, Tannishtha. "Asymmetry and Cell Fate in Stem Cells and Cancer." Blood 124, no. 21 (December 6, 2014): SCI—45—SCI—45. http://dx.doi.org/10.1182/blood.v124.21.sci-45.sci-45.

Full text

Abstract:

Abstract Our research focuses on the signals that control stem cell self-renewal and how these signals are hijacked in cancer. Using genetic models, we have shown that classic developmental signaling pathways such as Wnt and Hedgehog play key roles in stem cell growth and regeneration and are dysregulated during leukemia development. In addition, we have used real-time imaging strategies to show that stem cells have the capacity to undergo both symmetric and asymmetric division, and that shifts in the balance between these modes of division are controlled by the microenvironment and subverted by oncogenes. This work led to the discovery that regulators of asymmetric division, such as the cell fate determinant Musashi, can promote aggressive leukemias and may serve as critical targets for diagnostics and therapy in hematologic malignancies. Most recently, we have developed a high resolution in vivo imaging system that has allowed us to begin to map the behavior and interactions of stem cells with the microenvironment within living animals and to define how these change during cancer formation. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

26

Kalemkerian, Gregory P. "Staging and imaging of small cell lung cancer." Cancer Imaging 11, no. 1 (2011): 253–58. http://dx.doi.org/10.1102/1470-7330.2011.0036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Erasmus, Jeremy J., H. Page McAdams, and Edward F. Patz. "Non–Small Cell Lung Cancer: FDG-PET Imaging." Journal of Thoracic Imaging 14, no. 4 (October 1999): 247–56. http://dx.doi.org/10.1097/00005382-199910000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Xu, Hengyi, Zoraida P. Aguilar, Huaipeng Su, John Dixon, Hua Wei, and Andrew Wang. "Breast Cancer Cell Imaging using Semiconductor Quantum Dots." ECS Transactions 25, no. 11 (December 17, 2019): 69–77. http://dx.doi.org/10.1149/1.3236409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tofani, A., M. G. Scelsa, A. Semprebene, I. Venturo, M. Lopez, S. Giunta, and C. L. Maini. "Somatostatin receptors imaging in small cell lung cancer." Biomedicine & Pharmacotherapy 47, no. 6-7 (November 1993): 252. http://dx.doi.org/10.1016/0753-3322(93)90150-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Groshar, D. "FDG-PET Imaging in Small Cell Lung Cancer." Clinical Positron Imaging 2, no. 6 (December 1999): 330. http://dx.doi.org/10.1016/s1095-0397(99)00090-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Dimou, Anastasios, Carol Sherman, and John Wrangle. "Imaging in Advanced Non–Small Cell Lung Cancer." Journal of Thoracic Imaging 31, no. 4 (July 2016): 238–42. http://dx.doi.org/10.1097/rti.0000000000000219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

FLAMEN, P., A. BOSSUYT, J. DE GREVE, M. PIPELEERS-MARICHAL, F. KEUPPENS, and G. SOMERS. "Imaging of renal cell cancer with radiolabeled octreotide." Nuclear Medicine Communications 14, no. 10 (October 1993): 873–77. http://dx.doi.org/10.1097/00006231-199310000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Jelinek, J. S., J. Redmond, J. J. Perry, L. M. Burrell, R. A. Benedikt, C. A. Geyer, P. J. Peller, L. L. Wacks, B. J. Wise, and V. N. Ghaed. "Small cell lung cancer: staging with MR imaging." Radiology 177, no. 3 (December 1990): 837–42. http://dx.doi.org/10.1148/radiology.177.3.2173844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Berenger, N., J. L. Moretti, C. Boaziz, N. Vigneron, J. F. Morere, and J. L. Breau. "Somatostatin receptor imaging in small cell lung cancer." European Journal of Cancer 32, no. 8 (July 1996): 1429–31. http://dx.doi.org/10.1016/0959-8049(96)00078-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Daniel, Dianne C. "Breast cancer: Cell biology, clinical parameters, and imaging." Microscopy Research and Technique 59, no. 1 (September 19, 2002): 1–2. http://dx.doi.org/10.1002/jemt.10171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lu, Huiting, Keke Guo, Yu Cao, Fan Yang, Dongdong Wang, Lei Dou, Yayun Liu, and Haifeng Dong. "Cancer Cell Membrane Vesicle for Multiplex MicroRNA Imaging in Living Cells." Analytical Chemistry 92, no. 2 (December 23, 2019): 1850–55. http://dx.doi.org/10.1021/acs.analchem.9b03764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Shankar, Lalitha K., and Daniel C. Sullivan. "Functional Imaging in Lung Cancer." Journal of Clinical Oncology 23, no. 14 (May 10, 2005): 3203–11. http://dx.doi.org/10.1200/jco.2005.08.854.

Full text

Abstract:

Accurate detection of the presence and extent of disease is vital in the management of non–small-cell lung cancer. While computed tomography and magnetic resonance imaging tend to be the routine diagnostic modalities used in the management of lung cancer, there have been significant advances in the field of functional and molecular imaging. In this article, we review the performance of the functional imaging techniques that are currently available for the evaluation of non–small-cell lung cancer. The techniques range from evaluation of glucose metabolism in tumors with fluorodeoxyglucose, to evaluation of proliferation with fluorothymidine and evaluation of tumor hypoxia with agents such as fluoromisonidazole. Magnetic resonance imaging with an emphasis on dynamic contrast enhancement of tumors as well as detecting of malignant lymph nodes with targeted contrast agents is discussed. Emerging technologies such as lung imaging fluorescence endoscopy are considered. The role of functional imaging in planning, predicting response to, and evaluating effects of, various therapies is explored.

APA, Harvard, Vancouver, ISO, and other styles

38

Mudeng, Vicky, Gelan Ayana, Sung-Uk Zhang, and Se-woon Choe. "Progress of Near-Infrared-Based Medical Imaging and Cancer Cell Suppressors." Chemosensors 10, no. 11 (November 11, 2022): 471. http://dx.doi.org/10.3390/chemosensors10110471.

Full text

Abstract:

Diffuse optical tomography, an imaging modality that utilizes near-infrared light, is a new way to assess soft tissue. It provides a non-invasive screening of soft tissue, such as the breast in females and prostate in males, to inspect the existence of cancer. This new imaging method is considered cost-effective and preferred because the implementation is simply through the application of a laser or light-emitting diode as a light source. Near-infrared technology does not only offer cancer screening modality, but also acts as a cancer treatment method, called near-infrared photoimmunotherapy. Despite plentiful studies in the area of near-infrared technology for cancer imaging and cancer cell suppression, there is no consolidated review that provides an overview of near-infrared application in cancer cell imaging and therapy. The objective of this study is to review near-infrared-based medical imaging and novel approaches to eradicate cancer cells. Additionally, we have discussed prospective instrumentation to establish cancer therapeutics apparatuses based on near-infrared technology. This review is expected to guide researchers implementing near-infrared for a medical imaging modality and cancer suppression in vitro, in vivo, and in clinical settings.

APA, Harvard, Vancouver, ISO, and other styles

39

Rowland, Teisha J., Gabrijela Dumbović, Evan P. Hass, John L. Rinn, and Thomas R. Cech. "Single-cell imaging reveals unexpected heterogeneity of telomerase reverse transcriptase expression across human cancer cell lines." Proceedings of the National Academy of Sciences 116, no. 37 (August 26, 2019): 18488–97. http://dx.doi.org/10.1073/pnas.1908275116.

Full text

Abstract:

Telomerase is pathologically reactivated in most human cancers, where it maintains chromosomal telomeres and allows immortalization. Because telomerase reverse transcriptase (TERT) is usually the limiting component for telomerase activation, numerous studies have measured TERT mRNA levels in populations of cells or in tissues. In comparison, little is known about TERT expression at the single-cell and single-molecule level. To address this, we analyzed TERT expression across 10 human cancer lines using single-molecule RNA fluorescent in situ hybridization (FISH) and made several unexpected findings. First, there was substantial cell-to-cell variation in number of transcription sites and ratio of transcription sites to gene copies. Second, previous classification of lines as having monoallelic or biallelicTERTexpression was found to be inadequate for capturing theTERTgene expression patterns. Finally, spliced TERT mRNA had primarily nuclear localization in cancer cells and induced pluripotent stem cells (iPSCs), in stark contrast to the expectation that spliced mRNA should be predominantly cytoplasmic. These data reveal unappreciated heterogeneity, complexity, and unconventionality in TERT expression across human cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

40

Karam, Jose A., Ralph P. Mason, Kenneth S. Koeneman, Peter P. Antich, Elie A. Benaim, and Jer-Tsong Hsieh. "Molecular imaging in prostate cancer." Journal of Cellular Biochemistry 90, no. 3 (September 26, 2003): 473–83. http://dx.doi.org/10.1002/jcb.10636.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Chen, Mai-Lin, Xiao-Ting Li, Yi-Yuan Wei, Li-Ping Qi, and Ying-Shi Sun. "Diagnostic Value of Spectral CT Parameters in Differentiating Different Types of Lung Cancer." Journal of Medical Imaging and Health Informatics 10, no. 8 (August 1, 2020): 1804–8. http://dx.doi.org/10.1166/jmihi.2020.3189.

Full text

Abstract:

Background: This study proposed to quantitatively assess the value of spectral CT imaging parameters in differentiating different pathological types of lung cancer. Methods: Eighty five patients with lung cancer (66 non-mucinous adenocarcinomas, 7 Squamous cell carcinomas, 8 small cell carcinomas, 1 mucinous adenocarcinoma, 1 sarcomatoid carcinoma, 1 carcinoid, 1 large cell carcinoma) underwent CT plain scan, contrast enhanced CT scans in arterial phase (a) and venous phase (v) with spectral imaging mode on a GE Revolution Xtream CT scanner. The Spectral CT Imaging parameters: Iodine concentrations (IC) of lesion in arterial phase (ICLa) and venous phase (ICLv), Normalized IC (NICa/NICv)-normalized to the IC in the aorta, slope of the spectral HU curve (λHUa/λHUv) and monochromatic CT number (CT40keVa/CT40keVv, CT70keVa/CT70keVv) enhancement on 40 keV and 70 keV images were calculated. The One-way ANOVA or Kruskal-Wallis test was used to compare quantitative parameters among lung squamous carcinoma, small cell carcinoma and lung adenocarcinoma groups, Bonferroni method was used to correct P value for multiple comparisons. Results: Among the different pathological types of lung cancers, these quantitative parameters of spectral CT imaging CT70keVa has significant difference. The CT70keVa of lung adenocarcinoma was lower than small cell carcinoma (P = 0.048) and squamous cell carcinoma (P = 0.039), respectively. And these CT40keVa, CT70keVa/CT70keVv parameters of lung adenocarcinoma was lower than non-adenocarcinomas (P < 0.05). However, there was no significant difference in spectral CT parameters between small cell lung cancer and squamous cell lung cancer, small cell lung cancer and non-small cell carcinoma (P > 0.05). Conclusion: Spectral CT parameters may be of value in distinguishing different pathological types of lung cancer.

APA, Harvard, Vancouver, ISO, and other styles

42

Liu, Zhengwei, Faming Wang, Xinping Liu, Yanjuan Sang, Lu Zhang, Jinsong Ren, and Xiaogang Qu. "Cell membrane–camouflaged liposomes for tumor cell–selective glycans engineering and imaging in vivo." Proceedings of the National Academy of Sciences 118, no. 30 (July 22, 2021): e2022769118. http://dx.doi.org/10.1073/pnas.2022769118.

Full text

Abstract:

The dynamic change of cell-surface glycans is involved in diverse biological and pathological events such as oncogenesis and metastasis. Despite tremendous efforts, it remains a great challenge to selectively distinguish and label glycans of different cancer cells or cancer subtypes. Inspired by biomimetic cell membrane–coating technology, herein, we construct pH-responsive azidosugar liposomes camouflaged with natural cancer-cell membrane for tumor cell–selective glycan engineering. With cancer cell–membrane camouflage, the biomimetic liposomes can prevent protein corona formation and evade phagocytosis of macrophages, facilitating metabolic glycans labeling in vivo. More importantly, due to multiple membrane receptors, the biomimetic liposomes have prominent cell selectivity to homotypic cancer cells, showing higher glycan-labeling efficacy than a single-ligand targeting strategy. Further in vitro and in vivo experiments indicate that cancer cell membrane–camouflaged azidosugar liposomes not only realize cell-selective glycan imaging of different cancer cells and triple-negative breast cancer subtypes but also do well in labeling metastatic tumors. Meanwhile, the strategy is also applicable to the use of tumor tissue–derived cell membranes, which shows the prospect for individual diagnosis and treatment. This work may pave a way for efficient cancer cell–selective engineering and visualization of glycans in vivo.

APA, Harvard, Vancouver, ISO, and other styles

43

Niu, Mengda, Jingjing Qin, Liang Wang, Yujia He, Chuanhuizi Tian, Yanyan Chen, Pufeng Huang, and Zhiping Peng. "Evaluation of [18F]tetrafluoroborate as a Potential PET Imaging Agent in a Sodium Iodide Symporter-Transfected Cell Line A549 and Endogenous NIS-Expressing Cell Lines MKN45 and K1." Molecular Imaging 2022 (February 27, 2022): 1–13. http://dx.doi.org/10.1155/2022/2679260.

Full text

Abstract:

[18F]tetrafluoroborate (TFB) has been introduced as the 18F-labeled PET imaging probe for the human sodium iodide symporter (NIS). Noninvasive NIS imaging using [18F]TFB has received much interest in recent years for evaluating various NIS-expressing tumors. Cancers are a global concern with enormous implications; therefore, improving diagnostic methods for accurate detection of cancer is extremely important. Our aim was to investigate the PET imaging capabilities of [18F]TFB in NIS-transfected lung cell line A549 and endogenous NIS-expressing tumor cells, such as thyroid cancer K1 and gastric cancer MKN45, and broaden its application in the medical field. Western blot and flow cytometry were used to assess the NIS expression level. Radioactivity counts of [18F]TFB, in vitro, in the three tumor cells were substantially higher than those in the KI inhibition group in the uptake experiment. In vivo PET imaging clearly delineated the three tumors based on the specific accumulation of [18F]TFB in a mouse model. Ex vivo biodistribution investigation showed high [18F]TFB absorption in the tumor location, which was consistent with the PET imaging results. These results support the use of NIS-transfected lung cell line A549 and NIS-expressing tumor cells MKN45 and K1, to investigate probing capabilities of [18F]TFB. We also demonstrate, for the first time, the feasibility of [18F]TFB in diagnosing stomach cancer. In conclusion, this study illustrates the promising future of [18F]TFB for tumor diagnosis and NIS reporter imaging.

APA, Harvard, Vancouver, ISO, and other styles

44

Takahashi, Haruko, Daisuke Kawahara, and Yutaka Kikuchi. "Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies." Cancers 14, no. 17 (August 23, 2022): 4080. http://dx.doi.org/10.3390/cancers14174080.

Full text

Abstract:

Breast cancer is the most common cancer affecting women worldwide. Although many analyses and treatments have traditionally targeted the breast cancer cells themselves, recent studies have focused on investigating entire cancer tissues, including breast cancer cells. To understand the structure of breast cancer tissues, including breast cancer cells, it is necessary to investigate the three-dimensional location of the cells and/or proteins comprising the tissues and to clarify the relationship between the three-dimensional structure and malignant transformation or metastasis of breast cancers. In this review, we aim to summarize the methods for analyzing the three-dimensional structure of breast cancer tissue, paying particular attention to the recent technological advances in the combination of the tissue-clearing method and optical three-dimensional imaging. We also aimed to identify the latest methods for exploring the relationship between the three-dimensional cell arrangement in breast cancer tissues and the gene expression of each cell. Finally, we aimed to describe the three-dimensional imaging features of breast cancer tissues using noninvasive photoacoustic imaging methods.

APA, Harvard, Vancouver, ISO, and other styles

45

Kaynak, Ahmet, Harold W. Davis, Andrei B. Kogan, Jing-Huei Lee, Daria A. Narmoneva, and Xiaoyang Qi. "Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy." Cancers 14, no. 10 (May 21, 2022): 2536. http://dx.doi.org/10.3390/cancers14102536.

Full text

Abstract:

Cancer is among the leading causes of death worldwide. In recent years, many cancer-associated biomarkers have been identified that are used for cancer diagnosis, prognosis, screening, and early detection, as well as for predicting and monitoring carcinogenesis and therapeutic effectiveness. Phosphatidylserine (PS) is a negatively charged phospholipid which is predominantly located in the inner leaflet of the cell membrane. In many cancer cells, PS externalizes to the outer cell membrane, a process regulated by calcium-dependent flippases and scramblases. Saposin C coupled with dioleoylphosphatidylserine (SapC-DOPS) nanovesicle (BXQ-350) and bavituximab, (Tarvacin, human–mouse chimeric monoclonal antibodies) are cell surface PS-targeting drugs being tested in clinical trial for treating a variety of cancers. Additionally, a number of other PS-selective agents have been used to trigger cytotoxicity in tumor-associated endothelial cells or cancer cells in pre-clinical studies. Recent studies have demonstrated that upregulation of surface PS exposure by chemodrugs, radiation, and external electric fields can be used as a novel approach to sensitize cancer cells to PS-targeting anticancer drugs. The objectives of this review are to provide an overview of a unique dual-role of PS as a biomarker/target for cancer imaging and therapy, and to discuss PS-based anticancer strategies that are currently under active development.

APA, Harvard, Vancouver, ISO, and other styles

46

Condeelis, John, and Jeffrey E. Segall. "Intravital imaging of cell movement in tumours." Nature Reviews Cancer 3, no. 12 (December 2003): 921–30. http://dx.doi.org/10.1038/nrc1231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Choyke, Peter L. "Can Molecular Imaging Measure T-cell Activation?" Cancer Research 80, no. 14 (July 15, 2020): 2975–76. http://dx.doi.org/10.1158/0008-5472.can-20-1146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Linguanti, Flavia, Elisabetta Maria Abenavoli, Valentina Berti, and Egesta Lopci. "Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy." Cancers 14, no. 19 (September 27, 2022): 4700. http://dx.doi.org/10.3390/cancers14194700.

Full text

Abstract:

Chimeric antigen receptor–engineered (CAR) T cells are emerging powerful therapies for patients with refractory/relapsed B-cell lymphomas. [18F]FDG PET/CT plays a key role during staging and response assessment in patients with lymphoma; however, the evidence about its utility in CAR-T therapies for lymphomas is limited. This review article aims to provide an overview of the role of PET/CT during CAR-T cell therapy in B-cell lymphomas, focusing on the prognostic value of metabolic parameters, as well as on response assessment. Data from the literature report on the use of [18F]FDG PET/CT at the baseline with two scans performed before treatment started focused on the time of decision (TD) PET/CT and time of transfusion (TT) PET/CT. Metabolic tumor burden is the most studied parameter associated with disease progression and overall survival, making us able to predict the occurrence of adverse effects. Instead, for post-therapy evaluation, 1 month (M1) PET/CT seems the preferable time slot for response assessment and in this setting, the Deauville 5-point scale (DS), volumetric analyses, SUVmax, and its variation between different time points (∆SUVmax) have been evaluated, confirming the usefulness of M1 PET/CT, especially in the case of pseudoprogression. Additionally, an emerging role of PET/CT brain scans is reported for the evaluation of neurotoxicity related to CAR-T therapies. Overall, PET/CT results to be an accurate method in all phases of CAR-T treatment, with particular interest in assessing treatment response. Moreover, PET parameters have been reported to be reliable predictors of outcome and severe toxicity.

APA, Harvard, Vancouver, ISO, and other styles

49

Chansaenpak, Kantapat, Similan Tanjindaprateep, Nipha Chaicharoenaudomrung, Oratai Weeranantanapan, Parinya Noisa, and Anyanee Kamkaew. "Aza-BODIPY based polymeric nanoparticles for cancer cell imaging." RSC Advances 8, no. 69 (2018): 39248–55. http://dx.doi.org/10.1039/c8ra08145j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lauwerys, Louis, Evelien Smits, Tim Van den Wyngaert, and Filipe Elvas. "Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy." Biomedicines 10, no. 5 (May 5, 2022): 1074. http://dx.doi.org/10.3390/biomedicines10051074.

Full text

Abstract:

Cancer immunotherapy is an evolving and promising cancer treatment that takes advantage of the body’s immune system to yield effective tumor elimination. Importantly, immunotherapy has changed the treatment landscape for many cancers, resulting in remarkable tumor responses and improvements in patient survival. However, despite impressive tumor effects and extended patient survival, only a small proportion of patients respond, and others can develop immune-related adverse events associated with these therapies, which are associated with considerable costs. Therefore, strategies to increase the proportion of patients gaining a benefit from these treatments and/or increasing the durability of immune-mediated tumor response are still urgently needed. Currently, measurement of blood or tissue biomarkers has demonstrated sampling limitations, due to intrinsic tumor heterogeneity and the latter being invasive. In addition, the unique response patterns of these therapies are not adequately captured by conventional imaging modalities. Consequently, non-invasive, sensitive, and quantitative molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using specific radiotracers, have been increasingly used for longitudinal whole-body monitoring of immune responses. Immunotherapies rely on the effector function of CD8+ T cells and natural killer cells (NK) at tumor lesions; therefore, the monitoring of these cytotoxic immune cells is of value for therapy response assessment. Different immune cell targets have been investigated as surrogate markers of response to immunotherapy, which motivated the development of multiple imaging agents. In this review, the targets and radiotracers being investigated for monitoring the functional status of immune effector cells are summarized, and their use for imaging of immune-related responses are reviewed along their limitations and pitfalls, of which multiple have already been translated to the clinic. Finally, emerging effector immune cell imaging strategies and future directions are provided.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Cancer Cell Imaging'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles